CNS drug development carries high attrition; Synaptometric uses EEG biomarkers to translate preclinical signals to human trials.

CNS drug development is limited by poor translation from preclinical models to human outcomes, contributing to high attrition rates. Synaptometric is an EEG-based biomarker platform that enables cross-species translation from mouse to human, providing quantitative neural readouts to de-risk drug development, accelerate clinical trials, and support decision-making across a broad range of neurological and neuropsychiatric disorders.

Drug development, de-risking CNS drug development

Cross-species EEG biomarkers enable translation from mouse to human clinical trials.

CNS therapeutics market >$130B

Craig Erickson, MD; Ernie Pedapati, MD; Dave Hutten